{
  "ticker": "DVAX",
  "company_name": "Dynavax Technologies Corporation",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05506969",
      "title": "Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018\u00ae Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Plague, Pneumonic, Plague, Vaccine-Preventable Diseases",
      "start_date": "2022-08-09",
      "completion_date": "2024-04-26",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT03664648",
      "title": "DV2-HBV-27: Observational Pregnancy Registry",
      "status": "UNKNOWN",
      "phase": "",
      "condition": "Pregnant",
      "start_date": "2021-02-21",
      "completion_date": "2024-12",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT04193189",
      "title": "B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "HIV Infection, Hepatitis B",
      "start_date": "2020-12-14",
      "completion_date": "2024-08-13",
      "enrollment": 0,
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
    },
    {
      "nct_id": "NCT01282762",
      "title": "Long-Term Study on Safety and Immunogenicity of HEPLISAV\u2122 and Engerix-B\u00ae in Adults With Chronic Kidney Disease",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Chronic Kidney Disease",
      "start_date": "2010-12",
      "completion_date": "2013-08",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT01005407",
      "title": "Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Healthy",
      "start_date": "2010-02",
      "completion_date": "2011-05",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT00387738",
      "title": "Efficacy and Safety Study of TOLAMBA\u2122 in Ragweed-Allergic Adults",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Rhinitis, Allergic, Seasonal",
      "start_date": "2006-04",
      "completion_date": "2008-03",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT04385524",
      "title": "Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection",
      "status": "WITHDRAWN",
      "phase": "NA",
      "condition": "Hepatitis B Virus",
      "start_date": "2020-06-01",
      "completion_date": "2021-02-28",
      "enrollment": 0,
      "sponsor": "University of Louisville"
    },
    {
      "nct_id": "NCT00985426",
      "title": "Comparing Safety and Immunogenicity of HEPLISAV-B\u00ae to Engerix-B\u00ae in Chronic Kidney Disease (CKD) Patients",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chronic Kidney Disease",
      "start_date": "2009-09",
      "completion_date": "2012-01",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT03326752",
      "title": "Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Advanced Non Small Cell Lung Cancer",
      "start_date": "2017-09-20",
      "completion_date": "2019-09-19",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT00537355",
      "title": "An Evaluation of the Efficacy and Safety of TOLAMBA\u2122 for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Rhinitis, Allergic, Seasonal",
      "start_date": "2007-09",
      "completion_date": "2008-05",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    }
  ],
  "summary": {
    "total_trials": 30,
    "by_phase": {
      "PHASE2": 7,
      "": 2,
      "PHASE3": 6,
      "NA": 1,
      "PHASE1": 11,
      "PHASE1, PHASE2": 3
    },
    "by_status": {
      "COMPLETED": 21,
      "UNKNOWN": 1,
      "TERMINATED": 5,
      "WITHDRAWN": 1,
      "RECRUITING": 2
    },
    "active_trials": 2,
    "completed_trials": 21,
    "conditions": [
      "Advanced Non Small Cell Lung Cancer",
      "B-cell Lymphoma",
      "Chronic Hepatitis C",
      "Chronic Kidney Disease",
      "Colorectal Neoplasms",
      "End Stage Renal Disease",
      "End Stage Renal Disease on Hemodialysis (Diagnosis)",
      "HIV Infection, Hepatitis B",
      "HIV Infections",
      "Healthy",
      "Hepatitis B",
      "Hepatitis B Virus",
      "Hepatitis B, Chronic",
      "Metastatic Melanoma, Head Neck Cancer",
      "Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8",
      "Non-Hodgkin's Lymphoma",
      "Plague, Pneumonic, Plague, Vaccine-Preventable Diseases",
      "Pregnant",
      "Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis",
      "Rhinitis, Allergic, Seasonal",
      "Shingles, Herpes Zoster, Vaccine-Preventable Diseases"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:03.117971",
    "search_query": "Dynavax Technologies Corporation",
    "url": "https://clinicaltrials.gov/search?term=Dynavax+Technologies+Corporation"
  }
}